Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) BCL6 Antibodies:
anti-Human BCL6 Antibodies:
anti-Rat (Rattus) BCL6 Antibodies:
Go to our pre-filtered search.
Human Monoclonal BCL6 Primary Antibody for IHC, WB - ABIN2668887
García, García, Maestre, Lucas, Sánchez-Verde, Romero-Chala, Piris, Roncador: Genetic immunization: a new monoclonal antibody for the detection of BCL-6 protein in paraffin sections. in The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2005
Show all 2 Pubmed References
Human Polyclonal BCL6 Primary Antibody for IF (p), IHC (p) - ABIN749843
Szabó, Gáspár, Dajnoki, Papp, Fábos, Szegedi, Zeher: Expansion of circulating follicular T helper cells associates with disease severity in childhood atopic dermatitis. in Immunology letters 2017
Human Polyclonal BCL6 Primary Antibody for ELISA, ICC - ABIN6260236
Huang, Zhang, Hou, Wang, Liu, Zhang, Chen, Zhu: LncRNA AK023391 promotes tumorigenesis and invasion of gastric cancer through activation of the PI3K/Akt signaling pathway. in Journal of experimental & clinical cancer research : CR 2018
Human Polyclonal BCL6 Primary Antibody for WB - ABIN4283623
Margalit, Amram, Amariglio, Simon, Shaklai, Granot, Minsky, Shimoni, Harmelin, Givol, Shohat, Oren, Rechavi: BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma. in Blood 2006
BCL6 forms a complex with BCL6 corepressor (BCoR (show BCOR Antibodies)) on the promoters of selected Notch (show NOTCH1 Antibodies) target genes such as enhancer of split related 1.
this study shows that IL4 (show IL4 Antibodies) and IL21 (show IL21 Antibodies) cooperate to induce the high Bcl6 protein level required for germinal center formation
Although BCL6 controls follicular helper T cells activity in humans and mice, the role of miR (show MLXIP Antibodies)-31 is restricted to human follicular helper T cell differentiation, reflecting a species specificity of the miR (show MLXIP Antibodies)-31 action.
These findings indicate a role of the interaction between TH2-promoting factors and Bcl6 in promoting appropriate IL-4 (show IL4 Antibodies) production in mTH2 (show NUDT15 Antibodies) cells and suggest that chronic allergic diseases involve the TH2-promoting factor-mediated functional breakdown of Bcl6, resulting in allergy exacerbation.
Bioinformatics analysis and the dual-luciferase reporter assay demonstrated that miR (show MLXIP Antibodies)-10b could target the 3'-untranslated regions of B cell lymphoma 6 (Bcl6) which is an important regulator of osteoblast differentiation.
Def6 (show DEF6 Antibodies) limits proliferation of T follicular helper cells in mice via alteration of mTORC1 signaling and inhibition of Bcl6 expression.
The balance between CD4 (show CD4 Antibodies)(+) cytotoxic T cell and follicular helper T(Tfh) differentiation heavily depends on the class of infecting virus and is jointly regulated by the Tfh-related transcription factors Bcl6 and Tcf7 (show TCF7 Antibodies) (encoding TCF-1 (show HNF1A Antibodies)) and by the expression of the inhibitory receptors PD-1 (show PDCD1 Antibodies) and LAG3 (show LAG3 Antibodies).
Study provides evidence for an essential role of Bcl6 in the complex regulation of gene transcription during early adipogenesis. The action of Bcl6 is at least partially mediated by the direct transcriptional activation of STAT1 (show STAT1 Antibodies).
These data describe a novel regulatory mechanism through which STAT3 (show STAT3 Antibodies) and the Ikaros (show IKZF1 Antibodies) zinc finger transcription factors Aiolos (show IKZF3 Antibodies) and Ikaros (show IKZF1 Antibodies) cooperate to regulate Bcl-6 expression.
Our data reveal a regulatory role of BCL6 in inhibiting antiviral resistance factors in follicular Th cells
data provide a novel mechanism for positive control of gene expression by Bcl6, and illuminate how Bcl6 and Blimp1 (show PRDM1 Antibodies) control follicular helper T cell differentiation
our exploratory study suggests that EOMES, BCL6 and GZMB gene expression are aberrant within the PB T cell transcriptome of HT patients. The association of this transcription signature with the heterogeneity of HT and disease control is suggested.
Cryptic t(3;8)(q27;q24) and/or MYC (show MYC Antibodies)-BCL6 linkage associated with MYC (show MYC Antibodies) expression by immunohistochemistry is frequent in multiple-hit B-cell lymphomas
BCL6 overexpression in SHR reduced blood pressure, NLRP3 expression and inflammation in the renal cortex of SHR
Aberrant CD10 (show MME Antibodies) and BCL6 expression defines a subset of MCLs with higher mean Ki-67 (show MKI67 Antibodies) index and higher prevalence of MUM1 (show IRF4 Antibodies) expression
Double-hit lymphoma (DHL) is an aggressive form of DLBCL with an unmet treatment need, in which MYC (show MYC Antibodies) rearrangement is present with either BCL2 (show BCL2 Antibodies) or BCL6 rearrangement
BCL6 is a growth promoting factor in glioblastoma and glioma.
IFN gamma induced (show SAMHD1 Antibodies) upregulation of BCL6 was dependent on the classical STAT1 (show STAT1 Antibodies) signaling pathway, and affected both major BCL6 variants. Interestingly, although IFN alpha induced stronger STAT1 (show STAT1 Antibodies) phosphorylation than IFN gamma (show IFNG Antibodies), it only slightly upregulated BCL6 in multiple myeloma lines.
Findings demonstrate that BCL6 expression is downregulated by miR (show MLXIP Antibodies)-519d which targets its 3 '-UTR (show UTS2R Antibodies). Also, BCL6 mediates the repression of miR (show MLXIP Antibodies)-519d on cell proliferation and invasive capability of gastric cancer cells.
In Pakistani population, the frequency of GCB (show GBA Antibodies) type DLBCL [diffuse large B cell lymphoma ]expressing CD10 (show MME Antibodies) and BCL6 is 37.5%, and non- GCB (show GBA Antibodies) type DLBCL [diffuse large B cell lymphoma ] expressing MUM1 (show IRF4 Antibodies) is 62.5%.
The protein encoded by this gene is a zinc finger transcription factor and contains an N-terminal POZ domain. This protein acts as a sequence-specific repressor of transcription, and has been shown to modulate the transcription of START-dependent IL-4 responses of B cells. This protein can interact with a variety of POZ-containing proteins that function as transcription corepressors. This gene is found to be frequently translocated and hypermutated in diffuse large-cell lymphoma (DLCL), and may be involved in the pathogenesis of DLCL. Alternatively spliced transcript variants encoding different protein isoforms have been found for this gene.
B-cell CLL/lymphoma 6
, B-cell CLL/lymphoma 6 (zinc finger protein 51)
, B-cell lymphoma 6 protein
, zinc finger protein 51
, B-cell leukemia/lymphoma 5
, B-cell leukemia/lymphoma 6
, B-cell lymphoma 6 protein homolog
, B-cell lymphoma 5 protein
, B-cell lymphoma 6 protein transcript
, cys-his2 zinc finger transcription factor
, lymphoma-associated zinc finger gene on chromosome 3
, protein LAZ-3
, zinc finger and BTB domain-containing protein 27
, zinc finger transcription factor BCL6S